Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Other financing activities (2017 - 2025)

Immucell's Other financing activities history spans 14 years, with the latest figure at $24905.0 for Q2 2025.

  • For Q2 2025, Other financing activities fell 84.89% year-over-year to $24905.0; the TTM value through Dec 2025 reached $67880.0, down 60.03%, while the annual FY2025 figure was $67880.0, 1247.63% up from the prior year.
  • Other financing activities reached $24905.0 in Q2 2025 per ICCC's latest filing, down from $42975.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $270603.0 in Q3 2024 to a low of -$270603.0 in Q4 2024.
  • Average Other financing activities over 5 years is $36699.5, with a median of $33940.0 recorded in 2025.
  • Peak YoY movement for Other financing activities: tumbled 331.77% in 2024, then surged 753.19% in 2025.
  • A 5-year view of Other financing activities shows it stood at $78430.0 in 2021, then plummeted by 85.88% to $11075.0 in 2022, then plummeted by 665.9% to -$62673.0 in 2023, then crashed by 331.77% to -$270603.0 in 2024, then surged by 109.2% to $24905.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Other financing activities are $24905.0 (Q2 2025), $42975.0 (Q1 2025), and -$270603.0 (Q4 2024).